异动解读｜默沙东盘中上涨3.06%，mRNA癌症疫苗三期成功后多家机构上调评级持续提振

行情直击08-26 01:32

8月25日，默沙东盘中上涨3.06%，报155.27美元/股，成交额8.45亿美元。

消息面上，默沙东与Moderna联合开发的个性化mRNA癌症疫苗intismeran autogene联合Keytruda的III期临床试验INTerpath-001此前宣布达到无复发生存期主要终点及远处转移无生存期关键次要终点，数据公布后多家机构纷纷上调评级，持续提振股价表现。该联合疗法在完全切除的IIB-IV期黑色素瘤患者中展现出统计学显著且具有临床意义的改善，两家公司计划就申报提交事宜与监管机构展开沟通。此前Argus及大和证券等机构已上调默沙东目标价至143-145美元区间，当前股价已突破前期历史高点。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1107458616?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-26 01:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107458616","market":"hk","top_or_hot":-1,"title":"异动解读｜默沙东盘中上涨3.06%，mRNA癌症疫苗三期成功后多家机构上调评级持续提振","media":"行情直击","content":"<p><p>8月25日，默沙东盘中上涨3.06%，报155.27美元/股，成交额8.45亿美元。</p><p>消息面上，默沙东与Moderna联合开发的个性化mRNA癌症疫苗intismeran autogene联合Keytruda的III期临床试验INTerpath-001此前宣布达到无复发生存期主要终点及远处转移无生存期关键次要终点，数据公布后多家机构纷纷上调评级，持续提振股价表现。该联合疗法在完全切除的IIB-IV期黑色素瘤患者中展现出统计学显著且具有临床意义的改善，两家公司计划就申报提交事宜与监管机构展开沟通。此前Argus及大和证券等机构已上调默沙东目标价至143-145美元区间，当前股价已突破前期历史高点。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜默沙东盘中上涨3.06%，mRNA癌症疫苗三期成功后多家机构上调评级持续提振</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜默沙东盘中上涨3.06%，mRNA癌症疫苗三期成功后多家机构上调评级持续提振\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-26 01:32 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月25日，默沙东盘中上涨3.06%，报155.27美元/股，成交额8.45亿美元。消息面上，默沙东与Moderna联合开发的个性化mRNA癌症疫苗intismeran autogene联合Keytruda的III期临床试验INTerpath-001此前宣布达到无复发生存期主要终点及远处转移无生存期关键次要终点，数据公布后多家机构纷纷上调评级，持续提振股价表现。该联合疗法在完全切除的IIB-IV期...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"","article_id":"1107458616","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107458616","pubTimestamp":1787679162,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"8月25日，默沙东盘中上涨3.06%，报155.27美元/股，成交额8.45亿美元。消息面上，默沙东与Moderna联合开发的个性化mRNA癌症疫苗intismeran autogene联合Keytruda的III期临床试验INTerpath-001此前宣布达到无复发生存期主要终点及远处转移无生存期关键次要终点，数据公布后多家机构纷纷上调评级，持续提振股价表现。此前Argus及大和证券等机构已上调默沙东目标价至143-145美元区间，当前股价已突破前期历史高点。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"MRK":"默沙东"},"translate_title":"Interpretation of the change | Merck rose 3.06% in the intraday session. After the success of the third phase of the mRNA cancer vaccine, many institutions upgraded their ratings and continued to boost it","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"8月25日，默沙东盘中上涨3.06%，报155.27美元/股，成交额8.45亿美元。消息面上，默沙东与Moderna联合开发的个性化mRNA癌症疫苗intismeran autogene联合Keytruda的III期临床试验INTerpath-001此前宣布达到无复发生存期主要终点及远处转移无生存期关键次要终点，数据公布后多家机构纷纷上调评级，持续提振股价表现。该联合疗法在完全切除的IIB-IV期黑色素瘤患者中展现出统计学显著且具有临床意义的改善，两家公司计划就申报提交事宜与监管机构展开沟通。此前Argus及大和证券等机构已上调默沙东目标价至143-145美元区间，当前股价已突破前期历史高点。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107458616","isCrawlerRequest":true}